The Indian team wins big, again!
OPPI’s annual summit highlights important milestones for the pharmaceutical industry
Posted on March 26, 2022
Focus on the changing frontiers of health research and innovation in a dynamic and digitized world
Focused on redefining pharmaceutical research in a digitalized world, this edition of the Annual Summit of the Organization of Pharmaceutical Producers of India (OPPI) saw the participation of eminent experts from government and the pharmaceutical industry. The event took place virtually on March 23-24, 2022, during which ministers, government officials, global and local industry leaders, scientists, healthcare professionals, policy makers and academics deliberated and discussed strategies to strengthen the pharmaceutical industry in India.
With Accenture as a knowledge partner, the summit also saw the launch of two important reports: Multi-Regional Clinical Trials (MRCT) and the Value of OTC in India. While the former explores the possibilities of improving access to new treatments, technologies and diagnostics for Indian patients, the evolution of regulatory pathways by maximizing the digital approach and how multi-regional clinical trials can meet this challenge with promising results, the second reflects and elaborates on the current OTC regulations in the country and how we can collectively unlock optimal economic value for patients and the country as a whole.
The main guest of the summit, Shri. Bhagawanth Khuba, (Honourable Union Minister of State for Chemicals and Fertilizers and New and Renewable Energy, Government of India), commended the efforts of India and OPPI during the pandemic and highlighted the importance of digitalization in the pharmaceutical industry and the need for strong regulatory approvals to accelerate research on new biologics and generics in India. He talked about making India’s pharmaceutical industry $130 billion by 2030, by strengthening industry-academia collaborations and improving the curriculum to create a good academic foundation for the next generation of scientists.
Discussing the theme of the event, S Sridhar, Chairman of OPPI, said, “The pharmaceutical and healthcare ecosystem has experienced significant disruption since the onset of the pandemic, but despite the pandemic-induced disruptions, the industry has shown immense resilience to innovate for better results. and more effective solutions for COVID-19 while simultaneously encouraging capacity building to export medicines and vaccines for other diseases as well. The annual OPPI Summit builds on the relevance of innovation and rapid digitization in the healthcare and pharmaceutical sector with the aim of bringing together diverse stakeholders to chart the way forward for the pharmaceutical industry.
In addition, Ms. S. Aparna, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of Industry of India, highlighted the draft R&D policy which aims to simplify the regulatory landscape and encourages research-based public-private partnerships. Furthermore, eminent experts like Dr. Randeep Guleria, Director, AIIMS, New Delhi and Dr. Renu Swarup, Former Secretary, Department of Biotechnology, Ministry of Science and Technology, Government of India have highlighted the need for a forward-looking approach and the required preparation for the emerging challenges in health care in India. Both emphasized three essential elements: capacity building for labor and infrastructure, cutting-edge technologies, and national and international collaborations to scale up innovation.
Commenting on the event, KG Ananthakrishnan, Chief Executive Officer of OPPI, said: “We have all witnessed a paradigm shift with the COVID-19 pandemic and although the response has been swift, it has shown that we need a future-ready disease surveillance model. and take care of our people. OPPI’s annual summit highlighted how digitization has become an integral part of innovation and R&D and played to full effect in recent years. This move to digitize the country’s healthcare delivery system ushers in a new era of opportunity, with digitization being harnessed across the entire value chain – pharmaceutical innovation, diagnostics and disease management.
The COVID-19 pandemic has highlighted the need for research, innovation and development of science-based innovations at grassroots level, giving impetus to the journey of “Making to Discover and Innovate in India”. OPPI has recognized the contributions of industry stalwarts and renowned experts in the field of research and innovation. Dr. Cyrus S. Poonawalla, President and MD, Serum Institute of India received the Lifetime Achievement Award; Special Recognition Awards were given to Dr. Randeep Guleria, Director, AIIMS, New Delhi, and the Indian Medical Association. In addition to its Scientist of the Year awards, OPPI also introduced two new award categories this year; namely the Excellence in Innovation Healthcare Start-up of the Year 2021 award and the OPPI-QCI Quality Award for Excellent Facility, 2022, keeping in mind the importance of innovation and quality which should constitute the foundation of the industry in the future.
The 2 day event ended with some interesting takeaways from all the eminent speakers and panelists who deepened the conversations to aid in discovery, innovation and R&D for the pharmaceutical and healthcare industry. health.